Intranasal Acromegaly Treatment Gains Orphan Drug Designation

Octreotide is a somatostatin analog that suppresses excessive growth hormone production from pituitary adenomas.

An investigational drug to treat acromegaly has been granted Orphan Drug designation by the Food and Drug Administration (FDA).

Acromegaly is primarily caused by a benign pituitary adenoma and is characterized by the enlargement of the hands and feet, facial changes, hypertension, diabetes mellitus, and cardiomyopathy. DP1038 (octreotide acetate; Dauntless Pharmaceuticals), a somatostatin analog, uses the patented Intravail intranasal absorption technology developed by Aegis Therapeutics, offering patients a non-injectable alternative to treat this condition. 

Related Articles

A Phase 1 clinical study of DP1038 demonstrated robust safety and pharmacodynamic data in healthy subjects.

For more information call (858) 999-3053 or visit